for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Knight Therapeutics Inc

GUD.TO

Latest Trade

7.51CAD

Change

0.00(0.00%)

Volume

149,148

Today's Range

7.45

 - 

7.53

52 Week Range

7.10

 - 

8.69

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
7.51
Open
7.52
Volume
149,148
3M AVG Volume
4.53
Today's High
7.53
Today's Low
7.45
52 Week High
8.69
52 Week Low
7.10
Shares Out (MIL)
135.96
Market Cap (MIL)
1,021.02
Forward P/E
36.76
Dividend (Yield %)
--

Latest Developments

More

Medison Biotech Received Favorable Ruling From Israeli Courts In Response To Litigation Claim Brought By Knight Therapeutics CEO

Knight Therapeutics Reports Second Quarter 2019 Results

Knight Therapeutics And Pan-Canadian Pharmaceutical Alliance (PCPA) Reach Agreement For Probuphine For Opioid Dependence

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Knight Therapeutics Inc

Knight Therapeutics Inc is a Canada-based pharmaceutical company. The Company is engaged in developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products, consumer health products and medical devices in Canada and select international markets. It finances other life sciences companies in Canada and internationally. Its prescription pharmaceuticals and medical devices in various stages of development include Impavido, AzaSite, ATryn, Photofrin, ILUVIEN, TULSA-PRO, PROBUPHINE, Advaxis Family of Products, Ember Family of Products, NeurAxon Family of Products, Antibe Family of Products, Blood Factor Products and VEWS Vascular Early Warning System. In addition, the Company also has a portfolio of branded consumer health products, including Neuragen, Flat Tummy Tea, FOCUSFactor, FLEXISEQ, SEQuaderma, HandMD, UrgentRx, Laboratoire Dr. Renaud, Premiology and Pro-Derm.

Industry

Biotechnology & Drugs

Contact Info

3400 De Maisonneuve Blvd W

+1.514.4844483

https://www.gud-knight.com/

Executive Leadership

James C. Gale

Independent Chairman of the Board

Samira Sakhia

President, Chief Financial Officer, Director

Jonathan Ross Goodman

Chief Executive Officer, Director

Amal Khouri

Vice President - Business Development

Jody Engel

Director - Business Development

Key Stats

2.13 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (CAD)

2016

0.150

2017

0.120

2018

0.170

2019(E)

0.204
Price To Earnings (TTM)
28.85
Price To Sales (TTM)
76.95
Price To Book (MRQ)
1.02
Price To Cash Flow (TTM)
25.95
Total Debt To Equity (MRQ)
0.10
LT Debt To Equity (MRQ)
0.07
Return on Investment (TTM)
3.61
Return on Equity (TTM)
3.55

Latest News

Latest News

Latin American pharma Biotoscana confirms in sale talks: filing

Latin American pharmaceutical company Biotoscana Investments <GBIO33.SA> confirmed that its shareholders were in talks with investors about a sale, according to a securities filing on Monday.

Deals of the day-Mergers and acquisitions

The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

Knight Terapeutics and Eurofarma eye Biotoscana: source

Canada's Knight Terapeutics <GUD.TO> and Brazilian pharmaceuticals company Eurofarma are interested in acquiring control of Brazilian pharmaceutical company Biotoscana Investments SA <GBIO33.SA>, one source with knowledge of the matter said.

Knight Terapeutics and Eurofarma eye Biotoscana -Brazil Journal blog

Canada's Knight Terapeutics and Brazilian pharmaceuticals company Eurofarma are interested in acquiring control of Biotoscana Investments SA , financial blog Brazil Journal reported on Monday, citing unnamed sources.

CANADA STOCKS-TSX edges higher on robust earnings, energy rebound

Canada's main stock index rose on Wednesday, after two sessions of declines, as positive earnings and a rebound in energy stocks buoyed sentiment with focus on a crucial round of trade talks between the United States and China.

PRESS DIGEST- Canada-April 26

The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.

PRESS DIGEST - Canada - April 1

The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.

CANADA STOCKS-TSX gains on rise in energy shares

Canada's main stock index gained on Monday, helped by gains in energy shares on the back of higher crude prices.

PRESS DIGEST - Canada - March 1

The following are the top stories from selected Canadian newspapers. Reuters has not verified these stories and does not vouch for their accuracy.

BRIEF-Knight Therapeutics Says Qtrly Basic Earnings Per Share $0.05

* QTRLY REVENUES WERE $3.2 MILLION, AN INCREASE OF 80% OVER PRIOR PERIOD

BRIEF-Knight Therapeutics Announces Canadian Regulatory Approval For Probuphine For Opioid Drug Dependence

* KNIGHT THERAPEUTICS ANNOUNCES CANADIAN REGULATORY APPROVAL FOR PROBUPHINE™ FOR OPIOID DRUG DEPENDENCE Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Knight Therapeutics Says ‍Will Have Exclusive Rights To Market And Sell Tenapanor In Canada​

* KNIGHT THERAPEUTICS - LICENSE AGREEMENT WITH ARDELYX THAT PROVIDES KNIGHT WITH EXCLUSIVE RIGHTS TO COMMERCIALIZE TENAPANOR IN CANADA

BRIEF-Knight Reports Qtrly Basic Earnings Per Share $0.05

* Q4 EARNINGS PER SHARE VIEW C$0.04, REVENUE VIEW C$2.1 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Knight Therapeutics Says Medimetriks Pharma Has Prepaid $20 Mln Of Knight's $23 Mln Secured Strategic Loan Issued In 2016

* KNIGHT THERAPEUTICS INC - MEDIMETRIKS PHARMACEUTICALS HAS PREPAID US$20 MILLION OF KNIGHT'S US$23 MILLION SECURED STRATEGIC LOAN ISSUED IN 2016 Source text for Eikon: Further company coverage:

BRIEF-Knight Therapeutics Says New Drug Submission For Netildex Accepted For Review By Health Canada​

* KNIGHT THERAPEUTICS AND SIFI S.P.A. ANNOUNCE FILING OF NEW DRUG SUBMISSION FOR NETILDEX IN CANADA

BRIEF-KNIGHT THERAPEUTICS REPORTS Q3 EARNINGS PER SHARE $0.03

* ALL CURRENCIES ARE CANADIAN Source text for Eikon: Further company coverage:

BRIEF-Knight Therapeutics reports qtrly earnings per share $0.03

* Q3 earnings per share view C$0.03 -- Thomson Reuters I/B/E/S

BRIEF-Knight Therapeutics CFO Jeffrey Kadanoff steps down

* Jeffrey Kadanoff, CFO is leaving Knight effective October 13, 2017

BRIEF-Knight Therapeutics announces increase in ownership of Crescita Therapeutics

* Knight Therapeutics - pursuant to early warning requirements of national instrument 62-103, co announced increase in ownership of Crescita Therapeutics

BRIEF-Knight Therapeutics amended its secured loan agreement with Crescita Therapeutics

* Knight Therapeutics Inc - Amended its secured loan agreement with Crescita Therapeutics Inc

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up